| BMY |
Report |
Total revenue |
BEAT |
pred ~$11.86B vs. cons $11.73B |
MEDIUM |
| BMY |
Report |
Operating diluted EPS |
BEAT |
pred ~$1.62 vs. cons $1.60 |
MEDIUM |
| BMY |
Report |
Growth Portfolio revenue |
BEAT |
pred ~$7.15B vs. cons $7.04B |
MEDIUM |
| BMY |
Guide |
FY26 total revenue |
UNCHANGED |
guide ~$46.0–$47.5B vs. cons $47.45B |
MEDIUM |
| BMY |
Guide |
FY26 non-GAAP EPS |
UNCHANGED |
guide $6.05–$6.35 vs. cons $6.34 |
MEDIUM |
| BMY |
Guide |
FY26 Eliquis growth |
UNCHANGED |
guide +10%–15% vs. cons ~+12.9% |
MEDIUM |
| BMY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| BMY |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guidance after a beat likely fails to support further revisions |
LOW |